Menu

Alzheimer’s Should be Characterized by Biomarkers: Report

A proposed definition of the disease emphasizes signs of neurodegeneration and the presence of β-amyloid and tau, rather than cognitive symptoms.

Apr 10, 2018
Diana Kwon

Neurofibrillary tangles in the hippocampus of a patient with Alzheimer-related pathology.WIKIMEDIA, PATHO

Alzheimer’s disease should be defined by changes in the brain rather than cognitive symptoms such as memory decline, according to a report published today (April 10) in Alzheimer’s & Dementia

This proposal, which was put forth by the Alzheimer’s Association and the National Institute on Aging, suggests that Alzheimer’s patients should be defined by in vivo biomarkers, such as brain scans to identify neurodegeneration or spinal fluid tests to detect β-amyloid and tau, two proteins involved in the pathology of the disease.

“What we’re seeing now is that Alzheimer’s disease is defined by the presence of plaques and tangles in your brain,” Clifford Jack, a Mayo Clinic brain imaging specialist and coauthor of the report, tells NPR. Within this framework, he adds, “symptoms become the result of the disease, not the definition of the disease.”

Through this new definition, the number of people considered to have Alzheimer’s “will increase dramatically,” Jack tells the Associated Press. “There are a lot more cognitively normal people who have the pathology in the brain who will now be counted as having Alzheimer’s disease.”

The authors of the report note that this definition is meant to be used in observational and interventional research, not the clinic. “It’s a research framework meant to be tested, a tool for researchers, not for the doctor’s office,” coauthor Maria Carrillo, chief scientific officer of the Alzheimer's Association, tells NPR. She adds that biomarker-based tests could one day help prevent the disease, once effective drugs are available.

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.